Trial Profile
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Pemziviptadil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms VIP
- Sponsors PhaseBio Pharmaceuticals
- 04 Feb 2022 Status changed from suspended to discontinued. Reason the study was stopped: Terminated: Study drug resupply delayed (Covid-19).
- 19 Jan 2022 This trial has been discontinued in Austria (Date of the global end of the trial : 22-Dec-2021), according to European Clinical Trials Database record.
- 13 Jan 2022 This trial has been discontinued in Hungary, according to European Clinical Trials Database (22 Dec 2021)